Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
GlaxoSmithKline PLC banner

GlaxoSmithKline PLC
LSE:GSK

Watchlist Manager
GlaxoSmithKline PLC Logo
GlaxoSmithKline PLC
LSE:GSK
Watchlist
Price: 2 194.5 GBX 0.67% Market Closed
Market Cap: £89.5B
Write Note Create Alert Ask AI

Relative Value

The Relative Value of one GSK stock under the Base Case scenario is 1 433.26 GBX. Compared to the current market price of 2 194.5 GBX, GlaxoSmithKline PLC is Overvalued by 35%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GSK Relative Value
Base Case
1 433.26 GBX
Overvaluation 35%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

P/S
View Details
P/E
View Details
P/OCF
View Details
P/FCFE
View Details
P/B
View Details
EV/S
View Details
EV/GP
View Details
EV/EBITDA
View Details
EV/EBIT
View Details
EV/OCF
View Details
EV/FCFF
View Details
EV/IC
View Details

Multiples Across Competitors

GSK Competitors Multiples
GlaxoSmithKline PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
GlaxoSmithKline PLC
LSE:GSK
88.8B GBP 2.7 15.6 7.9 11.2
US
Eli Lilly and Co
NYSE:LLY
997.2B USD 15.3 48.3 32.5 34.6
US
Johnson & Johnson
NYSE:JNJ
578.6B USD 6.1 21.6 15 18.4
CH
Roche Holding AG
SIX:ROG
281.1B CHF 4.6 30 12.7 14.8
US
Merck & Co Inc
NYSE:MRK
303.5B USD 4.7 16.6 10.4 12.1
CH
Novartis AG
SIX:NOVN
230.9B CHF 5.3 21.2 13.1 16.8
UK
AstraZeneca PLC
LSE:AZN
216.1B GBP 5.2 32.1 15.3 22.4
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK 4.2 12.7 9.3 11
US
Pfizer Inc
NYSE:PFE
154.7B USD 2.5 19.9 7.4 9.9
US
Bristol-Myers Squibb Co
NYSE:BMY
125.6B USD 2.6 17.8 6.9 8.9
P/E Multiple
Earnings Growth PEG
UK
GlaxoSmithKline PLC
LSE:GSK
Average P/E: 23.6
15.6
18%
0.9
US
Eli Lilly and Co
NYSE:LLY
48.3
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
21.6
7%
3.1
CH
Roche Holding AG
SIX:ROG
30
29%
1
US
Merck & Co Inc
NYSE:MRK
16.6
14%
1.2
CH
Novartis AG
SIX:NOVN
21.2
15%
1.4
UK
AstraZeneca PLC
LSE:AZN
32.1
38%
0.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
12.7
7%
1.8
US
Pfizer Inc
NYSE:PFE
19.9
26%
0.8
US
Bristol-Myers Squibb Co
NYSE:BMY
17.8
17%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
GlaxoSmithKline PLC
LSE:GSK
Average EV/EBITDA: 42.2
7.9
2%
3.9
US
Eli Lilly and Co
NYSE:LLY
32.5
18%
1.8
US
Johnson & Johnson
NYSE:JNJ
15
2%
7.5
CH
Roche Holding AG
SIX:ROG
12.7
5%
2.5
US
Merck & Co Inc
NYSE:MRK
10.4
7%
1.5
CH
Novartis AG
SIX:NOVN
13.1
9%
1.5
UK
AstraZeneca PLC
LSE:AZN
15.3
10%
1.5
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.3
7%
1.3
US
Pfizer Inc
NYSE:PFE
7.4
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
6.9
-13%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
GlaxoSmithKline PLC
LSE:GSK
Average EV/EBIT: 90.5
11.2
12%
0.9
US
Eli Lilly and Co
NYSE:LLY
34.6
17%
2
US
Johnson & Johnson
NYSE:JNJ
18.4
6%
3.1
CH
Roche Holding AG
SIX:ROG
14.8
6%
2.5
US
Merck & Co Inc
NYSE:MRK
12.1
6%
2
CH
Novartis AG
SIX:NOVN
16.8
12%
1.4
UK
AstraZeneca PLC
LSE:AZN
22.4
23%
1
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11
8%
1.4
US
Pfizer Inc
NYSE:PFE
9.9
-1%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.9
-6%
N/A

See Also

Summary
GSK intrinsic value, competitors valuation, and company profile.
DCF Valuation
GSK stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GSK stock valuation using valuation multiples.
Wall Street Estimates
GSK price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GSK stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 316,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.